This observational analysis found precapillary pulmonary hypertension affects cancer patients significantly, suggesting a need for tailored therapeutic management.
Key Points
The incidence of precapillary pulmonary hypertension was observed in 22 out of 4568 cancer patients.
Key hemodynamic values showed an average mPAP of 41.7 mmHg, indicating severe pulmonary hypertension.
Most cases were classified as group 4 pulmonary hypertension, underscoring the association between cancer and this condition.
Results highlight the need for specialized cardio-oncology care in managing cancer patients with pulmonary hypertension.